Noncompaction cardiomyopathy medical therapy: Difference between revisions
No edit summary |
No edit summary |
||
Line 10: | Line 10: | ||
==Beta Blockade== | ==Beta Blockade== | ||
Noncompaction cardiomyopathy is assocatiated with an increased risk of arrhythmias including ventricular tachyarrhythmias. Beta blockade may reduce this risk. | Noncompaction cardiomyopathy is assocatiated with an increased risk of arrhythmias including ventricular tachyarrhythmias. Beta blockade may reduce this risk. | ||
==Angiotensin Converting Enzyme (ACE) Inhibition== | |||
Similar to other [[cardiomyopathies]], ACE inhibitors are indicated given the low [[cardiac output]] in these patients. | |||
==References== | ==References== |
Revision as of 11:18, 6 August 2011
Noncompaction Cardiomyopathy Microchapters |
Pathophysiology |
---|
Differentiating Noncompaction Cardiomyopathy from other Diseases |
Diagnosis |
Treatment |
Noncompaction cardiomyopathy medical therapy On the Web |
Risk calculators and risk factors for Noncompaction cardiomyopathy medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
The medical management of noncompaction cardiomyopathy is similar to that of other cardiomyopathies and includes the use of ACE inhibitors, beta blockers and aspirin.
Antiplatelet Therapy
Given the risk of embolization, these patients are generally treated with prophylactic aspirin.
Beta Blockade
Noncompaction cardiomyopathy is assocatiated with an increased risk of arrhythmias including ventricular tachyarrhythmias. Beta blockade may reduce this risk.
Angiotensin Converting Enzyme (ACE) Inhibition
Similar to other cardiomyopathies, ACE inhibitors are indicated given the low cardiac output in these patients.